Conquering Diseases

Study Of An Investigational Drug For Early Stage Er+/Her2- Breast Cancer


Seeking people who have who have already taken endocrine therapy for two to five years for their early-stage ER+/HER2- breast cancer and have a higher-than-average risk for their cancer to return for a study to compare the investigational drug to standard hormone therapy.


Participants in this study will be randomly assigned to get either the investigational drug or the standard hormone treatment. Both the participants and their doctor will know what medicine they are taking.

What we're hoping for

We are studying whether an investigational drug is better or worse than the standard hormone treatment for ER+/HER2- early breast cancer with an increased risk of recurrence.

Additional Information Identifier: NCT05514054

 Principal Investigator

Madhavi  Toke, MD

UMass Memorial Health

 Study Contact

The Cancer  Research Office



UMass Chan University Campus

55 Lake Ave North 

Worcester,MA 01655